Skip to main content

Advertisement

SpringerLink
Log in

High-field, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher field strength in patients with brain tumors

  • Diagnostic Neuroradiology
  • Published:
Neuroradiology Aims and scope Submit manuscript

Abstract

Introduction

To demonstrate intratumoral susceptibility effects in malignant brain tumors and to assess visualization of susceptibility effects before and after administration of the paramagnetic contrast agent MultiHance (gadobenate dimeglumine; Bracco Imaging), an agent known to have high relaxivity, with respect to susceptibility effects, image quality, and reduction of scan time.

Methods

Included in the study were 19 patients with malignant brain tumors who underwent high-resolution, susceptibility-weighted (SW) MR imaging at 3 T before and after administration of contrast agent. In all patients, Multihance was administered intravenously as a bolus (0.1 mmol/kg body weight). MR images were individually evaluated by two radiologists with previous experience in the evaluation of pre- and postcontrast 3-T SW MR images with respect to susceptibility effects, image quality, and reduction of scan time.

Results

In the 19 patients 21 tumors were diagnosed, of which 18 demonstrated intralesional susceptibility effects both in pre- and postcontrast SW images, and 19 demonstrated contrast enhancement in both SW images and T1-weighted spin-echo MR images. Conspicuity of susceptibility effects and image quality were improved in postcontrast images compared with precontrast images and the scan time was also reduced due to decreased TE values from 9 min (precontrast) to 7 min (postcontrast).

Conclusion

The intravenous administration of MultiHance, an agent with high relaxivity, allowed a reduction of scan time from 9 min to 7 min while preserving excellent susceptibility effects and image quality in SW images obtained at 3 T. Contrast enhancement and intralesional susceptibility effects can be assessed in one sequence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Reichenbach JR, Essig M, Haacke EM, Lee BC, Przetak C, Kaiser WA, Schad LR (1998) High-resolution venography of the brain using magnetic resonance imaging. MAGMA 6:62–69

    Article  PubMed  CAS  Google Scholar 

  2. Reichenbach JR, Haacke EM (2001) High-resolution BOLD venographic imaging: a window into brain function. NMR Biomed 14:453–467

    Article  PubMed  CAS  Google Scholar 

  3. Reichenbach JR, Jonetz-Mentzel L, Fitzek C, Haacke EM, Kido DK, Lee BC, Kaiser WA (2001) High-resolution blood oxygen-level dependent MR venography (HRBV): a new technique. Neuroradiology 43:364–369

    Article  PubMed  CAS  Google Scholar 

  4. Barth M, Nobauer-Huhmann IM, Reichenbach JR, Mlynarik V, Schoggl A, Matula C, Trattnig S (2003) High-resolution three-dimensional contrast-enhanced blood oxygenation level-dependent magnetic resonance venography of brain tumors at 3 Tesla: first clinical experience and comparison with 1.5 Tesla. Invest Radiol 38:409–414

    Article  PubMed  CAS  Google Scholar 

  5. Nobauer-Huhmann IM, Ba-Ssalamah A, Mlynarik V, Barth M, Schoggl A, Heimberger K, Matula C, Fog A, Kaider A, Trattnig S (2002) Magnetic resonance imaging contrast enhancement of brain tumors at 3 tesla versus 1.5 tesla. Invest Radiol 37:114–119

    Article  PubMed  Google Scholar 

  6. Noebauer-Huhmann IM, Pinker K, Barth M, Mlynarik V, Ba-Ssalamah A, Saringer WF, Weber M, Benesch T, Witoszynskyj S, Rauscher A, Reichenbach JR, Trattnig S (2006) Contrast-enhanced, high-resolution, susceptibility-weighted magnetic resonance imaging of the brain: dose-dependent optimization at 3 tesla and 1.5 tesla in healthy volunteers. Invest Radiol 41:249–255

    Article  PubMed  Google Scholar 

  7. Lin W, Mukherjee P, An H, Yu Y, Wang Y, Vo K, Lee B, Kido D, Haacke EM (1999) Improving high-resolution MR bold venographic imaging using a T1 reducing contrast agent. J Magn Reson Imaging 10:118–123

    Article  PubMed  CAS  Google Scholar 

  8. Sehgal V, Delproposto Z, Haacke EM, Tong KA, Wycliffe N, Kido DK, Xu Y, Neelavalli J, Haddar D, Reichenbach JR (2005) Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging 22:439–450

    Article  PubMed  Google Scholar 

  9. Sehgal V, Delproposto Z, Haddar D, Haacke EM, Sloan AE, Zamorano LJ, Barger G, Hu J, Xu Y, Prabhakaran KP, Elangovan IR, Neelavalli J, Reichenbach JR (2006) Susceptibility-weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses. J Magn Reson Imaging 24:41–51

    Article  PubMed  Google Scholar 

  10. Tynninen O, Aronen HJ, Ruhala M, Paetau A, Von Boguslawski K, Salonen O, Jaaskelainen J, Paavonen T (1999) MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Invest Radiol 34:427–434

    Article  PubMed  CAS  Google Scholar 

  11. Reichenbach JR, Barth M, Haacke EM, Klarhofer M, Kaiser WA, Moser E (2000) High-resolution MR venography at 3.0 Tesla. J Comput Assist Tomogr 24:949–957

    Article  PubMed  CAS  Google Scholar 

  12. Bagley LJ, Grossman RI, Judy KD, Curtis M, Loevner LA, Polansky M, Detre J (1997) Gliomas: correlation of magnetic susceptibility artifact with histologic grade. Radiology 202:511–516

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. MR Centre of Excellence, Department of Radiology, Medical University Vienna, Lazarettg. 14, 1090, Vienna, Austria

    K. Pinker, I. M. Noebauer-Huhmann, P. Szomolanyi, M. Weber, G. Grabner & S. Trattnig

  2. Department of Neurosurgery, Medical University Vienna, Vienna, Austria

    I. Stavrou & E. Knosp

  3. Institute of Neurology, Medical University Vienna, Vienna, Austria

    R. Hoeftberger

  4. Department of Neurosurgery, University Erlangen-Nuremberg, Erlangen, Germany

    A. Stadlbauer

Authors
  1. K. Pinker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. M. Noebauer-Huhmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Stavrou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Hoeftberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Szomolanyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Stadlbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Grabner
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E. Knosp
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. Trattnig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Trattnig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pinker, K., Noebauer-Huhmann, I.M., Stavrou, I. et al. High-field, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher field strength in patients with brain tumors. Neuroradiology 50, 9–16 (2008). https://doi.org/10.1007/s00234-007-0298-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00234-007-0298-x

Keywords

Search

Navigation